All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

Frontline Treatment Strategies in EGFR-Mutant NSCLC

home / case-based-peer-perspectives / wakelee-egfr-nsclc

Frontline Treatment Strategies in EGFR-Mutant NSCLC

Advertisement

A Case of EGFR-Mutant Non-Small Cell Lung Cancer

EP. 1: A Case of EGFR-Mutant Non-Small Cell Lung Cancer

May 15th 2018

Watch


Shifting Prognoses of Patients With EGFR-Mutant NSCLC

EP. 2: Shifting Prognoses of Patients With EGFR-Mutant NSCLC

May 15th 2018

Watch


EGFR-Mutant NSCLC: Optimizing Therapy Selection

EP. 3: EGFR-Mutant NSCLC: Optimizing Therapy Selection

May 15th 2018

Watch


Systemic Therapy Options for Non-Small Cell Lung Cancer

EP. 4: Systemic Therapy Options for Non-Small Cell Lung Cancer

May 15th 2018

Watch


Osimertinib's Value in EGFR-Mutant NSCLC

EP. 5: Osimertinib's Value in EGFR-Mutant NSCLC

May 15th 2018

Watch


EGFR-Mutant NSCLC: Selecting Patients for Osimertinib

EP. 6: EGFR-Mutant NSCLC: Selecting Patients for Osimertinib

May 15th 2018

Watch

Advertisement

Optimizing Therapy at Progression of EGFR-Mutant NSCLC

EP. 7: Optimizing Therapy at Progression of EGFR-Mutant NSCLC

May 15th 2018

Watch

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.